Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Saruta M, Takahara K, Fujita K, Minami T, Adachi T, Hirasawa Y, Hashimoto T, Ohno Y, Uemura H, Shiroki R, Azuma H, Kimura T. Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study. Int J Urol 2024;31:342-347. [PMID: 38113343 DOI: 10.1111/iju.15368] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 12/03/2023] [Indexed: 12/21/2023]

For:	Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Saruta M, Takahara K, Fujita K, Minami T, Adachi T, Hirasawa Y, Hashimoto T, Ohno Y, Uemura H, Shiroki R, Azuma H, Kimura T. Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study. Int J Urol 2024;31:342-347. [PMID: 38113343 DOI: 10.1111/iju.15368] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 12/03/2023] [Indexed: 12/21/2023]

Number

Cited by Other Article(s)

Uchimoto T, Matsuda T, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Tsuchida S, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma. Target Oncol 2024;19:635-644. [PMID: 38807017 DOI: 10.1007/s11523-024-01068-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/06/2024] [Indexed: 05/30/2024]

Abstract

BACKGROUND

Enfortumab vedotin (EV), an antibody-drug conjugate that targets Nectin-4, is used for patients with metastatic urothelial carcinoma who have experienced progression on platinum-based chemotherapy and checkpoint inhibitors. Despite the widespread use of the drug, evidence remains scarce regarding clinical indicators that can predict the response to EV treatment.

OBJECTIVE

We aimed to explore the predictive value of clinical indicators derived from peripheral blood tests for treatment responses to EV.

METHODS

We utilized records of 109 patients with metastatic urothelial carcinoma treated by EV from our multi-institutional dataset. Receiver operating characteristic curve analyses for predicting objective responses including several indicators from blood examinations, such as C-reactive protein-albumin ratio (CAR), hemoglobin, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and lactate dehydrogenase, were performed. The optimal cutoff points were determined by the Youden index. Logistic regression analyses for achieving objective responses to EV treatment were performed among these indicators.

RESULTS

The median age of the cohort was 74 years, and the median follow-up duration was 10 months for the entire group. Median overall survival and progression-free survival from the initiation of EV were 12 and 6 months, respectively. The objective response rate and disease control rate were 48% and 70%, respectively. The receiver operating characteristic curve analysis aimed at predicting the achievement of an objective response to EV showed that the concordant index for the CAR was 0.774, significantly surpassing other indicators such as hemoglobin level, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and serum lactate dehydrogenase. The Youden index identified an optimal cutoff value of 1 for CAR (mg/L for C-reactive protein and g/dL for serum albumin level) in predicting the objective response to EV treatment. Using the cutoff value for the CAR, the cohort was divided into 32 patients (29%) with lower CAR and 77 patients (71%) with higher CAR. The objective response rate was observed to be 84% in the lower CAR group and 32% in the higher CAR group (p < 0.0001). A logistic regression analysis revealed that an Eastern Cooperative Oncology Group Performance Status ≥1 (p = 0.04) and a CAR ≥1 (p < 0.001) were identified as independent predictors for the objective response to EV.

CONCLUSIONS

The evaluation of the CAR from a concise blood examination at the initiation of EV could effectively predict the treatment response to EV in patients with metastatic urothelial carcinoma after the progression of platinum-based chemotherapy and checkpoint inhibitors.

Collapse

Affiliation(s)

Taizo Uchimoto Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
Takuya Matsuda Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
Kazumasa Komura Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan. Division of Translational Research, Department of Urology, Osaka Medical and Pharmaceutical University, Daigaku-machi 2-7, Takatsuki, Japan.
Wataru Fukuokaya Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
Takahiro Adachi Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan
Yosuke Hirasawa Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan
Takeshi Hashimoto Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan
Atsuhiko Yoshizawa Department of Urology, Fujita-Health University School of Medicine, Kutsukake, Toyoake, Aichi Nagoya, Japan
Masanobu Saruta Department of Urology, Fujita-Health University School of Medicine, Kutsukake, Toyoake, Aichi Nagoya, Japan
Mamoru Hashimoto Department of Urology, Faculty of Medicine, Kindai University, Osakasayama, Osaka, Japan
Takuya Higashio Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
Shuya Tsuchida Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
Kazuki Nishimura Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
Takuya Tsujino Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
Ko Nakamura Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
Tatsuo Fukushima Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
Kyosuke Nishio Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
Shutaro Yamamoto Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
Kosuke Iwatani Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
Fumihiko Urabe Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
Keiichiro Mori Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
Takafumi Yanagisawa Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
Shunsuke Tsuduki Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
Kiyoshi Takahara Department of Urology, Fujita-Health University School of Medicine, Kutsukake, Toyoake, Aichi Nagoya, Japan
Teruo Inamoto Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
Jun Miki Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan
Kazutoshi Fujita Department of Urology, Faculty of Medicine, Kindai University, Osakasayama, Osaka, Japan
Takahiro Kimura Department of Urology, The Jikei University School of Medicine, 3-25-8, Nishi-shimbashi, Minato-ku, Tokyo, 105-8461, Japan.
Yoshio Ohno Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan
Ryoichi Shiroki Department of Urology, Fujita-Health University School of Medicine, Kutsukake, Toyoake, Aichi Nagoya, Japan
Hirotsugu Uemura Department of Urology, Faculty of Medicine, Kindai University, Osakasayama, Osaka, Japan
Haruhito Azuma Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan

Collapse

Uemura K, Ito H, Jikuya R, Kondo T, Tatenuma T, Kawahara T, Ito Y, Komeya M, Muraoka K, Hasumi H, Uemura H, Makiyama K. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data. Int J Urol 2024;31:678-684. [PMID: 38402449 DOI: 10.1111/iju.15437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2023] [Accepted: 02/14/2024] [Indexed: 02/26/2024]

Morikawa T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Iida K, Isobe T, Noda Y, Shimizu N, Aoki M, Gonda M, Banno R, Kubota H, Ando R, Umemoto Y, Kawai N, Yasui T. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers (Basel) 2024;16:1725. [PMID: 38730675 PMCID: PMC11083374 DOI: 10.3390/cancers16091725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 04/24/2024] [Accepted: 04/26/2024] [Indexed: 05/13/2024] Open

Affiliation(s)

Toshiharu Morikawa Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Taku Naiki Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.) Department of Urology, Nagoya City University West Medical Center, Nagoya 467-8601, Japan
Yosuke Sugiyama Department of Pharmacy, Nagoya City University Hospital, Nagoya 467-8601, Japan;
Aya Naiki-Ito Department of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan;
Takashi Nagai Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Toshiki Etani Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Keitaro Iida Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Teruki Isobe Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Yusuke Noda Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.) Department of Urology, Anjo Kosei Hospital, Anjo 446-8602, Japan
Nobuhiko Shimizu Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Maria Aoki Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.) Department of Urology, Nagoya City University West Medical Center, Nagoya 467-8601, Japan
Masakazu Gonda Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Rika Banno Department of Urology, Konan Hospital, Konan 483-8704, Japan;
Hiroki Kubota Department of Urology, Kainan Hospital, Yatomi 498-8502, Japan;
Ryosuke Ando Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Yukihiro Umemoto Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.) Department of Urology, Nagoya City University West Medical Center, Nagoya 467-8601, Japan
Noriyasu Kawai Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Takahiro Yasui Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)

Collapse

Taguchi S. Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study. Int J Urol 2024;31:348. [PMID: 38183313 DOI: 10.1111/iju.15387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2024]